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April 24, 2012:1570–3electrocardiogram changes. Physicians are unlikely to immediately
discharge that group. However, our findings suggest that AMI
remains extremely unlikely and alternative diagnoses can be con-
sidered at an early stage.
Drs. Kavsak and Worster question the diagnostic performance
of hs-cTnT using the limit of detection (LoD) (5 ng/l) rather than
the limit of blank (LoB) (3 ng/l) as a cutoff. At the LoD cutoff, 272
(38.7%) patients would have had AMI immediately “ruled out” in
our prospective cohort study. Three AMIs would have been
missed. Thus, sensitivity fell to 97.7% (95% confidence interval
[CI]: 93.4% to 99.5%) with a negative predictive value of 98.9%
(95% CI: 96.8% to 99.8%). In our subsequent evaluation of
hs-cTnT in clinical practice, 195 (21.3%) patients had an initial
hs-cTnT below the LoD and only 2 developed elevated levels
(14 ng/l) on subsequent testing. Thus, sensitivity was 99.7%
(95% CI: 98.8% to 100.0%) with negative predictive value 99.0%
(95% CI: 96.3% to 99.9%). It remains to be decided whether these
results can be confirmed in other datasets and whether the clinical
community will find these results acceptable.
Recently, there has been discussion about reporting only down
to the LoD rather than to the LoB. Our findings may influence
that discussion. If the LoB provides important clinical data, this
fact should be considered. Indeed, we reported a sensitivity of
100.0% at the LoB in our cohort study (Reichlin et al. [3] and,
ore recently, Christ et al. [4] also reported the same sensitivity)
nd a 99.8% value in a cohort from clinical practice. Our findings
ertainly suggest that further work is necessary to improve the
nalytical precision of troponin assays at that level.
In our cohort study, samples were not repeated when hemolysis
as present, although we understand that hemolysis can lower
s-cTnT levels (4). Fifty-four (7.7%) of the samples in our cohort
tudy showed some degree of hemolysis. Twelve of those samples
ad values 3 ng/l, which is below the LoB. We would advocate
epeating the sample before excluding AMI at any cutoff whether
t be the LoB or the LoD. No AMIs were missed using this
pproach, although the number of patients affected was small.
Our findings are preliminary. They require further prospective
alidation and subsequent evaluation in a randomized controlled
rial. However, approaches like these are required to move the field
orward by reducing the time taken to exclude AMI. We believe
hat we should, over time, be able to unencumber emergency
epartments by developing innovative approaches for ruling out
MI. Our investigation starts that important work.
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Microvolt T-Wave Alternans
Testing Has a Role in
Arrhythmia Risk Stratification
In one interesting aspect, the letter by Jackson et al. (1) pertains to
risk stratification in general. They suggest that evidence-based
cardiac risk assessment should be an automatic process devoid of
individual clinical judgment. We disagree and maintain that any
risk assessment requires careful interpretation by experienced
physicians. Unfortunately, the Glasgow group misrepresented our
guideline statement (2) not only in this respect.
The presence of abnormal T-wave alternans (TWA) has
demonstrated clinical utility in stratifying risk for malignant
arrhythmias and sudden cardiac death. This derives from
prospective, peer-reviewed studies involving 12,000 patients.
These data clearly show that patients with increased TWA
levels have 2- to 23-fold independently higher risk of serious
outcomes as compared with those with lower TWA levels.
Elevated TWA provides risk information independent of left
ventricular ejection fraction (LVEF), standard clinical variables
(e.g., age and sex), and important cardiovascular risk markers
(e.g., smoking, diabetes, hypertension, and medication usage).
Our assertion, “it is reasonable to consider TWA evaluation
whenever there is suspicion of vulnerability to lethal cardiac
arrhythmias,” concurs with prior statements by the American
Heart Association (3,4), the American College of Cardiology
(3,4), and the National Institutes of Health (5).
As with any risk stratification method, including LVEF, not
all studies are consistent with the overall trend. Specifically, in
the MASTER (Microvolt T-Wave Alternans Testing for Risk
Stratification of Post-Myocardial Infarction Patients) trial and
TWA substudy of SCD-HeFT (Sudden Cardiac Death in
Heart Failure Trial), TWA did not predict appropriate im-
plantable cardioverter-defibrillator (ICD) therapy, sudden car-
diac death, and/or ventricular tachycardia/fibrillation. As dis-
cussed in our document (2), there are plausible explanations for
this departure from the bulk of the literature. Specifically, a
recent systematic review and meta-analysis determined that
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April 24, 2012:1570–3withdrawal of beta-adrenergic blockade before TWA assess-
ment diminishes its predictive strength by nearly 4-fold (6).
This observation also applies to the reduced predictivity in other
prospective studies.
Furthermore, it carries the important implication that TWA is
sensitive to chronic therapy (7), supporting our assertion that
TWA assessment should be performed while patients are on their
usual, chronic medications.
Regarding the potential application of TWA to guide therapy,
we stated, “there is as yet no definitive evidence from interventional
trials that it can guide therapy” (2). However, this conclusion does
not connote an absence of evidence or the impossibility of using
TWA to support other risk markers, especially in borderline cases.
The ABCD (Alternans Before Cardioverter Defibrillator) trial
demonstrated that TWA testing appears to be comparable to
electrophysiological study in guiding ICD implantation and that
the 2 methods may be complementary. Numerous studies outlined
in our document demonstrate that TWA provides additive pre-
dictive value to LVEF and other risk stratifiers. These facts are
reflected in our recommendation that TWA should not be used as
a sole parameter either to rule in or to rule out the prescription of
ICD therapy.
Thus, even without dedicated trials on therapy guidance, a
sizeable number of prospective studies support TWA’s utility in
risk stratification for life-threatening arrhythmias and its potential
value in clinical judgment.
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EFERENCES
1. Jackson CE, Myles RC, Cobbe SM, Petrie MC, McMurray JJV.
Microvolt T-wave alternans testing has no role at present in guiding
therapy for patients at high risk of ventricular arrhythmias (letter). J Am
Coll Cardiol 2012;59:854.
2. Verrier RL, Klingenheben T, Malik M, et al. Microvolt T-wave
alternans: physiologic basis, methods of measurement, and clinical
utility. Consensus guideline by the International Society for Holter and
Noninvasive Electrocardiology in collaboration with Japanese Circula-
tion Society, Computers in Cardiology Working Group of European
Society of Cardiology, and European Cardiac Arrhythmia Society.
J Am Coll Cardiol 2011;58:1309–24.
3. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006
guidelines for management of patients with ventricular arrhythmias and
the prevention of sudden cardiac death: a report of the American
College of Cardiology/American Heart Association Task Force and the
European Society of Cardiology Committee for Practice Guidelines
(Writing Committee to Develop Guidelines for Management of Pa-
tients With Ventricular Arrhythmias and the Prevention of Sudden
Cardiac Death). J Am Coll Cardiol 2006;48:e247–346.
4. Goldberger JJ, Cain ME, Hohnloser SH, et al. American Heart
Association/American College of Cardiology Foundation/Heart
Rhythm Society scientific statement on noninvasive risk stratification
techniques for identifying patients at risk for sudden cardiac death. A
scientific statement from the American Heart Association Council on
Clinical Cardiology Committee on Electrocardiography and Arrhyth-
mias and Council on Epidemiology and Prevention. J Am Coll Cardiol
2008;52:1179–99.
5. Fishman GI, Chugh SS, DiMarco JP, et al. Sudden cardiac death
prediction and prevention: report from a National Heart, Lung, and
Blood Institute and Heart Rhythm Society workshop. Circulation
2010;122:2335–48.
6. Chan PS, Gold MR, Nallamothu BK. Do beta-blockers impact microvolt
T-wave alternans testing in patients at risk for ventricular arrhythmias? A
meta-analysis. J Cardiovasc Electrophysiol 2010;21:1009–14.
7. Verrier RL, Nieminen T. T-wave alternans as a therapeutic marker for
antiarrhythmic agents. J Cardiovasc Pharmacol 2010;55:544–54.
